drugset / Trial / NCT00826514

An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis

NCT00826514

Phase 2 Completed 62 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.

Timeline

Start
2009-03-25
Primary completion
2010-01-11
Completion
2010-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 20 mg Intravenous

Indications